Scholar Rock Holding Corporation said the United States Food and Drug Administration review of apitegromab for spinal muscular atrophy will continue using a second U.S. fill-finish facility after Catalent Indiana received an Official Action Indicated inspection classification. The biotechnology company continues to anticipate an FDA decision by the September 30, 2026 Prescription Drug User Fee Act action date, although apitegromab remains investigational and the review outcome is not assured.
The development substantially changes the manufacturing route supporting the resubmitted Biologics License Application without reopening the central clinical question around apitegromab. Scholar Rock plans, under FDA guidance, to remove Catalent Indiana, which is part of Novo Nordisk, from the application and proceed solely with its second fill-finish facility.
That distinction matters because apitegromab’s regulatory history has already been shaped by manufacturing rather than a rejection of its pivotal efficacy package. When the FDA issued a Complete Response Letter in September 2025, Scholar Rock reported that the letter was related solely to observations at Catalent Indiana and did not cite additional approvability concerns involving apitegromab’s efficacy and safety data or its third-party drug substance manufacturer.
The second manufacturing site therefore represents more than conventional supply redundancy. It has become the principal operational pathway through which Scholar Rock could still convert a positive Phase 3 programme into a U.S. commercial product in 2026.
Why does Catalent Indiana’s OAI classification matter if apitegromab’s clinical package was not rejected?
An Official Action Indicated classification is a significant FDA inspection outcome. It indicates that a facility is considered to be in an unacceptable state of compliance and that regulatory or administrative action is recommended. It does not, by itself, determine whether a particular drug is safe or effective, nor does it necessarily mean that every product handled at the facility is defective.
For Scholar Rock, however, the classification is particularly important because Catalent Indiana had already been the manufacturing issue behind apitegromab’s first Complete Response Letter.
The FDA inspected the Bloomington, Indiana operation in 2025 and subsequently issued a warning letter describing significant current Good Manufacturing Practice violations. Scholar Rock and the facility operator continued remediation work, and an April 2026 inspection was expected to help determine whether Catalent could again support the apitegromab application.
The August 7 notification that the April inspection had been classified OAI effectively ended Catalent’s role as one of the two near-term regulatory routes supporting the BLA.
Scholar Rock is not waiting for that facility to be reclassified before seeking an apitegromab decision. Instead, the company has chosen to remove Catalent from the application and concentrate the FDA review on the second facility.
That strategy limits exposure to a manufacturing issue that has already delayed the programme once. It does not eliminate manufacturing risk, because the alternative facility must still satisfy the FDA requirements applicable to the BLA.
Can Scholar Rock’s second fill-finish facility support an FDA decision by September 30?
The strongest element of Scholar Rock’s latest update is that the second facility was not added after the Catalent OAI decision as an emergency substitute.
Scholar Rock had already discussed the alternative site with the FDA during a Type C meeting in March 2026. The resubmitted BLA subsequently included both Catalent Indiana and the second U.S.-based facility, providing two possible manufacturing paths to an approval decision.
According to the company, the FDA and Scholar Rock agreed during that meeting on the data package required to evaluate the second site. Scholar Rock said that package has now been submitted ahead of the agreed timeline and that the agency review is progressing.
The company has not publicly named the alternative facility. It has described the site as a U.S.-based operation that manufactures multiple commercial products and is in good standing with both the FDA and European Medicines Agency.
Importantly for launch planning, Scholar Rock also says commercial quantities of apitegromab vials produced at the second facility are already available. Those vials are at a third-party provider awaiting packaging and labelling for commercial distribution if the FDA approves the therapy.
This considerably shortens the distance between a regulatory decision and potential product availability. It still should not be interpreted as evidence that approval is effectively complete. Manufacturing-site qualification is part of the regulatory review, and the FDA must determine whether the revised application, including the remaining facility, satisfies applicable standards.
The September 30 PDUFA date is therefore still meaningful, but the path toward it has become narrower.
What does the SAPPHIRE trial actually show about apitegromab on top of existing SMA therapy?
The regulatory manufacturing story is unusually important because apitegromab already has a substantial late-stage clinical evidence package.
The pivotal Phase 3 SAPPHIRE study was a 52-week, double-blind, randomised, placebo-controlled trial involving 188 patients with nonambulatory Type 2 or Type 3 spinal muscular atrophy. All participants continued receiving an established SMN-targeted treatment, either nusinersen or risdiplam.
The main efficacy population consisted of 156 patients aged two to 12 years. Participants were randomised to receive apitegromab at 10 mg/kg, apitegromab at 20 mg/kg or placebo by intravenous infusion every four weeks. Another 32 patients aged 13 to 21 years formed an exploratory population.
In the primary analysis, the combined apitegromab dose groups produced a 1.8-point treatment difference versus placebo on the Hammersmith Functional Motor Scale Expanded at week 52, with a p-value of 0.0192.
A prespecified secondary analysis found that 30.4% of patients receiving apitegromab achieved at least a three-point improvement on the Hammersmith scale compared with 12.5% receiving placebo.
There is an important statistical nuance. The 20 mg/kg dose considered separately produced a 1.4-point difference versus placebo and did not independently reach conventional statistical significance, with a reported p-value of approximately 0.11. The primary endpoint was met using the prespecified combined-dose analysis.
That does not negate the positive primary result, but it illustrates why the evidence should be described precisely rather than reducing SAPPHIRE to a simple claim that every dose comparison was independently positive.
The trial was subsequently published in The Lancet Neurology, giving the pivotal evidence a stronger level of maturity than topline or conference-only data.
Scholar Rock has reported that no new safety findings emerged in SAPPHIRE and that serious adverse events were consistent with the underlying disease and background treatment, with none assessed as related to apitegromab. Safety interpretation will ultimately depend on the FDA’s assessment and, if approved, the final prescribing information.
Where could apitegromab fit as the spinal muscular atrophy treatment market becomes more competitive?
Apitegromab is being developed around a different biological strategy from therapies that address survival motor neuron protein.
The fully human monoclonal antibody selectively binds pro-myostatin and latent myostatin in skeletal muscle, inhibiting myostatin activation. Rather than replacing the defective SMN1 gene or increasing functional SMN protein through SMN2, the strategy is intended to improve muscle function in patients who continue to have functional deficits despite disease-modifying treatment.
That positioning could be commercially important because SAPPHIRE evaluated apitegromab as an add-on to nusinersen or risdiplam rather than as a replacement for them.
The competitive landscape, however, has moved forward while Scholar Rock has navigated its manufacturing delay.
Novartis gained U.S. approval for Itvisma in November 2025 for adults and pediatric patients aged two years and older with a confirmed SMN1 mutation, extending gene replacement therapy to a much broader age population. The FDA also approved a higher-dose regimen of Biogen’s Spinraza in March 2026, while Roche’s Evrysdi remains another major chronic SMN-targeted option.
Apitegromab therefore would not enter a static market.
Its potential differentiation rests on whether clinicians, patients and payers see enough incremental value in directly targeting muscle after, or alongside, therapy focused on the underlying SMN deficiency.
That creates an unusual commercial proposition. Scholar Rock does not necessarily need apitegromab to displace established SMA therapies. Its opportunity could instead depend on becoming an additional treatment layer for patients who retain substantial motor deficits.
The same model also creates a reimbursement challenge. Payers would be evaluating the incremental clinical benefit and cost of adding another chronic therapy to patients who may already be receiving expensive disease-modifying treatment.
Why manufacturing readiness is now almost as important as the Phase 3 results for Scholar Rock
Scholar Rock has spent much of 2026 preparing for the possibility that apitegromab could move rapidly from regulatory review into commercial launch.
The company said its U.S. commercial organisation is already active with SMA prescribers and treatment centres. Management has repeatedly said that Scholar Rock intends to launch apitegromab immediately after an FDA approval, subject to final regulatory and operational requirements.
The availability of commercial vials from the second fill-finish facility is important in that context. Regulatory approval without validated, releasable commercial inventory can create a second delay between an FDA decision and actual market supply.
Scholar Rock appears to have attempted to reduce that risk by manufacturing supply before the regulatory decision and moving vials to a third-party packaging and labelling provider.
The financial commitment is also becoming substantial. Scholar Rock ended June 2026 with approximately $492.1 million in cash, cash equivalents and marketable securities. The company recorded no revenue during the second quarter and reported a net loss of approximately $109.9 million as it funded clinical development and prepared for commercialisation.
That balance sheet provides significant resources, but the transition from development-stage biotechnology company to commercial rare-disease organisation will bring a different cost structure. Sales infrastructure, distribution, patient access programmes, inventory management and payer engagement all become more important if apitegromab receives approval.
What does removing Catalent Indiana mean for the European apitegromab review?
The Catalent development also reaches beyond the United States.
Apitegromab’s Marketing Authorisation Application remains under European Medicines Agency review, but the European submission included Catalent Indiana as the fill-finish facility. Scholar Rock is now discussing with the EMA how to incorporate its second facility into that application.
The company has said it will update expectations for the timing of a Committee for Medicinal Products for Human Use opinion after reaching alignment with the EMA.
That means the U.S. regulatory path currently has greater timeline visibility than the European process.
The second facility could ultimately provide a common manufacturing route for both jurisdictions, which would simplify supply planning if apitegromab gains approvals in multiple markets. Before that can happen, however, Scholar Rock must satisfy the separate regulatory requirements of each authority.
The September 30, 2026 FDA action date has consequently become the most immediate test of the apitegromab programme, but it should not be viewed simply as another referendum on whether the Phase 3 trial worked.
SAPPHIRE has already produced a positive primary endpoint, its results have been peer reviewed, and the previous Complete Response Letter did not identify additional approvability concerns involving efficacy or safety. The unresolved issue has been whether Scholar Rock can support the biologic with an acceptable commercial manufacturing chain.
By removing Catalent Indiana and advancing with the second fill-finish facility, Scholar Rock has created a route around the obstacle that stopped apitegromab in 2025. The next question is whether that alternative route is sufficiently mature for the FDA to complete the journey by September 30.
